Related Experiment Video
Updated: Mar 27, 2026

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
Published on: November 3, 2016
[Psychomotor retardation and intermitent convulsions for 8 months in an infant]
Yuan Ding1, Xi-Yuan Li, Yu-Peng Liu
1Department of Pediatrics, Peking University First Hospital, Beijing 100034, China. organic.acid@126.com.
Insights
Maternal phenylketonuria (PKU) caused a boy's psychomotor retardation and epilepsy. Family investigation is crucial for diagnosing developmental issues linked to parental conditions like PKU.
Area of Science:
- Medical Genetics
- Pediatric Neurology
- Metabolic Disorders
Background:
- Phenylketonuria (PKU) is an inherited metabolic disorder.
- Maternal PKU can lead to severe developmental issues in offspring.
- Early diagnosis and management are critical for preventing complications.
Observation:
- A 20-month-old boy presented with psychomotor retardation, epilepsy, and microcephaly.
- Brain MRI revealed white matter demyelination and ventricular abnormalities.
- Genetic analysis identified a homozygous mutation in the phenylalanine hydroxylase (PAH) gene in the mother, confirming PKU.
Findings:
- The boy exhibited developmental quotient of 43 and epilepsy, consistent with fetal exposure to high phenylalanine levels.
- The mother had undiagnosed PKU with markedly elevated blood phenylalanine levels.
- The child was heterozygous for the PAH gene mutation, inheriting one copy from his mother.
Implications:
- This case highlights the importance of family history and genetic screening in diagnosing developmental disorders.
- Undiagnosed maternal PKU can cause significant, preventable brain damage in children.
- Comprehensive clinical and metabolic evaluations of parents are essential for identifying disease-associated risks in offspring.
Abstract:
This study reports a boy with psychomotor retardation and epilepsy due to maternal phenylketonuria (PKU). The boy was admitted at the age of 20 months because of psychomotor retardation and epilepsy. He had seizures from the age of 1 year. His development quotient was 43. He presented with microcephaly, normal skin and hair color. Brain MRI scan showed mild cerebral white matter demyelination, broadening bilateral lateral ventricle and foramen magnum stricture. Chromosome karyotype, urine organic acids, blood amino acids and acylcarnitines were normal. His mother had mental retardation from her childhood. She presented with learning difficulties and yellow hair. Her premarriage health examinations were normal. She married a healthy man at age of 26 years. When she visited us at 28 years old, PKU was found by markedly elevated blood phenylalanine (916.54 μmol/L vs normal range 20-120 μmol/L). On her phenylalanine hydroxylase (PAH) gene, a homozygous mutations c.611A>G (p.Y204C) was identified, which confirmed the diagnosis of PAH-deficient PKU. Her child carries a heterozygous mutation c.611A>G with normal blood phenylalanine. Her husband had no any mutation on PAH. It is concluded that family investigation is very important for the etiological diagnosis of the children with mental retardation and epilepsy. Carefully clinical and metabolic survey should be performed for the parents with mental problems to identify parental diseases-associated child brain damage, such as maternal PKU.
More Related Videos
Related Concept Videos
REM Sleep Behavior Disorder
RBD is significantly associated with...
Inborn Errors of Metabolism
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Intellectual Disability
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Pharmacokinetics in Pediatric Patients: Drug Metabolism

